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Abstract
Background: The management of drug safety with the collection of reliable safety data during the conduction of clinical 
trials conduct is essential for the registry and marketing of products. The systematic evaluation of this process, based on 
objective measures, requires the application of quality instruments. This study was aimed to design and validate eight 
instruments through the components of quality (structure, process, and results), for characterizing and assessing the 
process of drug safety management, during the conduction of clinical trials. 
Methods: The eight instruments were designed according to the international recommendations for Good Clinical 
Practice (GCP) and comprise a knowledge survey for professionals at the investigational sites, a satisfaction scale of 
internal and external clients and a satisfaction survey for patients with the treatment of the adverse events. The instruments 
also include a checklist to evaluate the safety management infrastructure (human, material and organizational resources) 
in the sponsoring center, a checklist to evaluate the same criterion at the investigational sites and three checklists that 
evaluate adherence to regulatory requirements of essential documents (investigator’s brochure, protocol, and informed 
consent form). The content validity was evaluated by Delphi method and the reliability was determined by Cronbach α 
test. 
Results: All the items were valued as very adequate after the second round of the expert panel. The instruments were 
deemed as appropriate and understandable in the pre-test performed. All responders agreed with the options given and 
the accessibility of the application. Only 10% of professionals at the research sites suggested that the knowledge survey 
was too long. Cronbach α values between .66 and .93 were obtained.
Conclusion: The structure, process, and outcome framework allowed for the characterization of drug safety management 
during clinical trials, providing a useful approach for the promoter to systematically measure and evaluate the process. 
The eight instruments were deemed as reliable, feasible and easy to be used for examining drug safety management while 
carrying out clinical trials. 
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Implications for policy makers
• To decide if a new drug can be included in a therapeutic guide, the policy-makers need reliable safety data.
• Given the strong commitment of the pharmaceutical industry to drug and patient safety, while conducting clinical trials, it must provide policy-
makers with evidence to prove that safety management in these investigations is adequate.
• The pharmaceutical sponsors can strengthen the drug safety management process taking into account the perception of all the clinical trials 
stakeholders.
• To increase the reliability of safety data of a new drug, all the instruments used for measuring the quality of safety management during clinical 
trials, need to be validated, even those based on the current regulatory norms. 
• As the emphasis is on transparency, applicability, and communication, this approach to assess drug safety management should maximize the 
impact of these data to all stakeholders and decision-makers.
Implications for the public
The application of the instruments validated in this study helps to strengthen the process of obtaining drug safety data in clinical trials. The greater 
the number and quality of the information of the investigational drug safety obtained in a clinical trial, the lesser is the likelihood that serious adverse 
drug reactions will occur after the commercialization. Thus, the population will use the drug with a higher level of confidence, and clinicians will 
have more information about the drug safety profile. All of these contribute to guarantee the patient’s safety.
Key Messages 
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Background 
The management of clinical trials is an important element 
to achieve their implementation with the highest quality.1 
Among the processes that take place during the conduct of 
a clinical trial, the safety management of new investigational 
products is a key process that begins at early stages of research 
in humans and spreads throughout the lifetime of the product. 
This process involves the collection and periodic analyses 
of all safety data, including non-serious adverse events 
and laboratory data of clinical trial patients. This process 
also includes the assessment and submission in time to the 
regulators and all other stakeholders of expedited reports of 
serious, unexpected and with causal relationship events. In 
addition, it includes the preparation and submission of annual 
safety update reports, signal detection, and risk management 
activities, including the preparation of risk management 
plans.2 
Clinical trials sponsors systematically emphasize the need for 
a proper management of clinical trial for obtaining a successful 
product development,3 Many of them have implemented tools 
such as clinical trial management systems (CTMSs) that 
include different kinds of applications for the drug safety 
data collection and evaluation (eg, the Oracle applications 
integrated system4,5 and Alas Clinica6,7). In addition, the 
Patient-Reported Outcomes version of the Common 
Terminology Criteria for Adverse Events (PRO-CTCAE), a 
measurement system developed to improve the precision and 
reliability of patient-reported adverse events in clinical trials.8 
It has been developed other tools such as a screening system 
for the early detection and treatment of any condition based 
on laboratory results, which may have a possible relationship 
with drugs and allows feedbacks the results to the physician.9 
Another intelligent tools have been designed and have been 
applied new statistical approaches for visualizing safety data, 
providing creative ways to present the information, assist in 
spotting trends and signals and enhance data review.10,11 
However, difficulties persist when it comes to measuring 
quality, making it difficult to ascertain whether adequate 
quality is being achieved and also, to verify that processes 
designed to promote quality are doing so.12 Some gaps were 
identified such as inconsistencies in adverse effects reported. 
The adverse events are not usually pre-specified and occur 
their misclassification.13 Sometimes the way quality of safety 
information been processed within the surveillance function 
is not proper,10 or the promoter does not have adequate 
resources to achieve systematic risk assessment.14 
On the other hand, there is a need of evaluating the 
effectiveness of risk communications of drug safety 
information to healthcare providers and the public,14,15 even 
during pre-registration development; as well as to evaluate 
the satisfaction of the participants in the process with the risk 
information they receive.16 
Although regulatory agencies around the world and the 
pharmaceutical industry are taking a more comprehensive and 
holistic approach to safety evaluation in drug development,17-21 
many current clinical development and drug safety systems 
were not designed proactively, wisely or to manage risks as 
required by the comprehensive list of regulations for drug 
safety and risk management. So, these new regulations mean 
that the compliance per se is a necessary prerequisite but 
does not control the situation itself, and it is not suitable for 
demonstrating the safety of products and the risk management 
accurately.14 
Despite the usefulness of applying risk monitoring to safety 
aspects in the clinical trial, the use of objective metrics 
from the real clinical trials also support the sponsor level of 
data evaluation and they are significant tools to accelerate 
the improvement of the quality of clinical trials data in the 
industry.22 This requires the application of surveys, checklists 
and other instruments that will serve as a systematic data 
source. The instruments and indicators can take part of 
a true safety and risk management integrated system that 
delivers results and controls the overall risk management 
perception. 
We do not find any specific instrument for the evaluation of 
the drug safety management in terms of quality during the 
conduct of clinical trials process. This study was performed 
with the aim of designing and validating some instruments 
to assess drug safety management, as part of a strategy to 
strengthen the process of obtaining safety data during the 
conduct of clinical trials. 
Methods
Content Validation
The methodological sequence of three fundamental phases 
(preliminary, exploratory and final) was followed.23,24 In the 
preliminary phase it was formed the coordinating group,25 
composed by the author and two experienced academic 
researchers on the topic studied and the methodology used.
The eight instruments were designed at this phase: a 
knowledge survey for professionals at the investigational 
sites, a satisfaction scale of internal and external clients 
and a satisfaction survey for patients with the treatment of 
the adverse events. Also include a checklist to evaluate the 
safety management infrastructure (human, material and 
organizational resources) at the sponsoring center, a checklist 
to evaluate the same criterion at the investigational sites and 
finally, three checklists that evaluate adherence to regulatory 
requirements of essential documents (investigator’s brochure, 
protocol, and informed consent form) (see Supplementary 
file 1, Section 1).
A framework stablished by Donabedian26 based on quality 
constructs (structure, process, and outcomes) was used for 
describing and measuring the process (see Figure). The initial 
elements for characterizing the structure and process of the 
safety management in the first versions of the instruments 
were drafted in the form of items or questions. These were 
defined according to the recommendations of the Guideline 
for Good Clinical Practice (GCP) of the International 
Conference of Harmonization27 and the Report of the Council 
for International Organization of Medical Sciences (CIOMS) 
Working Group VI.28 
As a measure of the process result, it was evaluated 
the satisfaction of the following stakeholders: patients, 
investigators and co-investigators at the investigational 
sites, members of research ethics committees, specialist 
of the company’s regulatory affairs department and the 
regulatory agency.
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Afterwards, the coordinating group carried out the analysis, 
discussion, and qualitative adjustment to achieve the first 
version.
To the end of this phase, an intentional sampling was used 
for a possible expert selection that would integrate a panel 
for the evaluation of the content validity of the instruments. 
According to the methodological needs and peculiarities 
of each instrument, it was an imperative the selection of 
professionals having the following criteria:
• To work as a clinician, nurse, researching manager, 
clinical trial monitor, or specialist of the national drug 
regulatory agency. 
• To have five or more years of experience related to safety 
management in pre-registration clinical research.
• To have completed a course on clinical safety, GCP or 
clinical trials.
Twenty-five professionals were invited to participate. In 
October 2013, a self-appraisal questionnaire was sent to 
professionals (see  Supplementary file 1, Section 2) with the 
purpose to collect self-assessment on each of their competence 
in the sources of discussion that supported this approach, 
using e-mail as a means of distribution and collection. From 
the questionnaire results, the level of competence of each 
expert was determined following the methodology employed 
by Hurtado29:
1-	 The level of knowledge was measured on a scale of 11 
categories (0 to 10, where 0 represents the absence of 
knowledge on the subject treated and 10, full knowledge). 
The candidate has to tick his level of knowledge 
somewhere on the scale, according to his own self-
assessment. The knowledge coefficient (Kc) was formed 
multiplying the level of knowledge by 0.1.
2-	 It was estimated the coefficient of argumentation (Ka) of 
each expert from the analysis that he makes of the sources 
that allowed him to argue his criteria. For this, each 
respondent was asked to indicate in an ordinal scale of 
three categories (high, medium, or low level) the degree 
of influence they have had in their level of competence 
reached each of the following sources of argument: 
• Theoretical analyzes linked to the safety management 
during the conduct of clinical trials.
• Experience gained in the practice regarding safety 
management.  
• Reviewed works of national authors on the subject. 
• Reviewed works by international authors on the 
subject. 
• Knowledge of the state of safety management abroad.
To assign numerical values to each source of argument 
according to the degree of influence were attributed the 
values of the standard table used by Hurtado.29 The number 
of points obtained in total, corresponding to the value of the 
argumentation coefficient, was calculated by the following 
formula:
1 2 3 4 5 6( ),Ka ni n n n n n n= = + + + + +∑
where Ka: Argumentation coefficient, ni: Value corresponding 
to the source of argument i (1 to 6).
3- Based on the information of the questionnaires, the 
competition coefficient (K) is determined using the following 
formula: 
 
2
Kc KaK +=  Were considered:
High-level of competence: 0.8 ≤ K ≤ 1 
Medium level of competence: 0.5 ≤ K ≤ 0.8 
Low-level of competence: K < 0.5.
Exploratory phase (November-December 2013): the 
coordinating group e-mailed to the expert members of 
the panel the first version of the instruments and the 
corresponding validation guide (see  Supplementary file 1, 
Section 3), with the purpose to obtain their opinion about 
the usefulness of the proposals concerning the quality of its 
performance and the effectiveness that this first application 
could present. 
The validation guides were organized as a single ordinal scale 
Likert type,30 in which appropriateness must designate a scale 
from one to five (one represents a maximum full disagreement 
6 
 
evaluate the safety management infrastructure (human, material and organizational resources) 1 
at the sponsoring center, a checklist to evaluate the same criterion at the investigational sites 2 
and finally, three checklists that evaluate adherence to regulatory requirements of essential 3 
documents (investigator´s brochure, protocol, and informed consent form) (see Appendix 1). 4 
A framework stablished by Donabedian26 based on quality constructs (structure, process, and 5 
outcomes) was used for describing and measuring the process (see Figure 1). The initial 6 
elements for characterizing the structure and process of the safety management in the first 7 
versions of the instruments were drafted in the form of items or questions.  These were defined 8 
according to the recommendations of the Guideline for Good Clinical Practice (GCP) of the 9 
International Conference of Harmonization27 and the Report of the Council for International 10 
Organization of Medical Sciences (CIOMS) Working Group VI.28  11 
As a measure of the process result, it was evaluated the satisfaction of the following 12 
stakeholders: patients, investigators and co-investigators at the investigational sites, members 13 
of research ethics committees, specialist of the company's regulatory affairs department and the 14 
regulatory agency. 15 
 16 
 17 
 18 
 19 
 20 
 21 
 22 
 23 
 24 
 25 
 26 
Fig 1. Feature measured in each instrument and the quality component that represent. 27 
Afterwards, the coo dinating group carried out the analysis, discussion, and qualit tiv  28
adjustment to achieve the first version. 29 
To t e nd of this phase, an intentional sampling was used for a possible expert selection that 30 
would integrate a panel for the evaluation of the content validity of the instruments. According 31 
Structure  
Process   
Outcome 
•  Level of the professionals' knowledge about 
the drug safety management in clinical trials. 
 
• Infrastructure in the company for the drug 
safety management.  
• Infrastructure in the investigational sites for 
the drug safety management. 
• Adherence of the safety information in the 
Investigational Brochure. 
• Adherence of the safety information in the 
protocol. 
• Adherence of the safety information in the 
informed consent document. 
Human resources 
(Competence)  
Material resources 
(Infrastructure) 
 Definition of safety 
requirements in the 
essential documents 
 
Satisfaction of the clients 
with the process 
 
• Satisfaction of the internal and external clients.  
• Satisfaction of patients with the treatment of 
adverse events. 
Quality component and their measuring criteria           Issue of the instrument 
Figure. Feature Measured in Each Instrument and the Quality Component That Represent.
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while five, shows full agreement), and the response categories 
were described by using the following linguistic qualifiers:
5) Very adequate (VA): The item or question wish optimally 
reflects the theme, concept or specific content that it tries 
to measure. It can provide the total grasping of that content 
for clarity in writing (comprehension) and adequacy of the 
response options (for knowledge and satisfaction surveys). 
4) Quite adequate (QA): The item or question that expresses 
in a quite high degree, the theme, or specific content that 
it tries to measure. Although it requires some drafting 
modification is an adequate response option and provide a 
high level acquisition of the content.
3) Adequate (A): The item or question that takes into account 
an important part of the qualities of the subject or specific 
item that it tries to measure. Although it can be improved by 
the experts modifying some part of the text.
2) Little adequate (LA): The item or question that reflects a 
low level of adjusted theme. The concept or specific content 
that it tries to measure must be considered. This category 
involves a low adequate level of the evaluated subject. The text 
may be modified from the expert point of view.
1) Inadequate (I): The aspect with marked limitations and 
contradictions. It is that one which not allowed expressing the 
essential qualities of the concept or specific content item. It 
is intended to measure, but ideas are not stated correctly. It 
implies the failure of grasping or understanding the element 
in question and, consequently, brings about the deletion of 
the item.
In all the items, the experts might include additional free 
observations, assess the number of questions or extension of 
the items, and suggest the modification or, when necessary, 
make proposals for new items. 
The statistical and quantitative analyses of the content 
validation for the proposals generated in previous phase 
were performed using the Delphi method,31,32 and a manual 
version of the Torgerson mathematical model according to 
Moráguez,33 converting the ordinal scale into interval scale 
(from qualitative to quantitative) with the intention to provide 
objectivity to the experts’ judgment. The steps are:
1. To obtain the observed frequency
2. To obtain the accumulated frequency 
3. To obtain the relative accumulated frequency 
4. To allocate the value of the image corresponding to each 
obtained relative cumulative frequency from the Z-table of 
the normal distribution
5. To obtain the points through the calculation of N-AR 
where:
    
            .     ( )  
Summation of Sum by Aspects
No of Valuation Ranges x Number of A
N
spects
=
and AR = Average value for each item or question.
The line is divided by categories from the cut-off and the N-P 
points are located to determine the category of each aspect.
     
.    
Summation of Sum by AspectsCut off
No of Aspects to Evaluate
- =
The cut-offs obtained for each category of evaluation (VA, 
QA, A, LA or I) determined the reach of their range limit. 
If the subtraction of the limit value (N) minus the average 
value of the item (AR) is less than the cutoff of the category 
then the final evaluation for this item or question is the same 
category. If the subtraction of the limit value (N) minus the 
average value of the item (AR) is greater than the cutoff of the 
category then the final evaluation for this item or question is 
the next category. At the end of the final round, the level of 
consensus (C) was reached for each item or question, by the 
expression:
1 100n
t
VC
V
  
= - ×  
   
Where Vn = Negative votes, Vt = Total votes .
Decision rule: If C ≥ 75%, it means that there is a consensus 
among experts, but if it otherwise, (C <75%), another round 
of consultation should be held up to reach an agreement.33
Considering the modifications, adaptations or clarifications of 
the experts, a new proposal of each instrument was designed 
after the first round. 
Final phase: a summary with all responses was sent to the 
panel members as a feedback measure and they were asked to 
newly complete the questionnaire validation as well as giving 
their opinions, regarding the ones that differed from the rest. 
The level of consensus is determined for each instrument 
after each round, and so forth until arriving at a consensus. 
Pre-test
A pre-test was carried out to each instrument with the 
objective of detecting interpretation errors and clearing up 
the lists of items or questions. The responders were asked to 
show their agreement with the drafting and understanding 
of the item, adequacy of the response options, application 
easiness and the extension of each instrument. 
Previously, the persons responsible for the application of the 
instruments were instructed and trained.
The number of participants in the pre-test were the following: 
twenty professionals of the investigational sites for the 
knowledge survey, five patients, three internal and two 
external clients for the satisfaction scales, two professionals 
of the sponsor center and five of the investigational sites 
for the safety management infrastructure checklists, and 
three professionals for the checklists that assess adherence 
to regulatory requirements of the investigator brochures, 
protocols and informed consent documents respectively. 
Evaluation of Reliability
Cronbach α internal consistency coefficient was determined 
for the evaluation of the reliability of all the instruments. The 
interpretation should be that the more the value approach 
to 1, the greater will be the reliability. Almost all the alfa 
values over .70 are considered acceptable and over .80, good 
values.30,32
Results 
Content Validation
Twenty-five professionals were invited to form the panel of 
experts, but only seventeen agreed to participate. As result 
of the evaluation of the level of competence, eight of the 
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professionals with a high level of competence were selected, 
and two with the highest score in the category of the medium 
level (see Table).
The results of the content validation for the first five 
instruments (the knowledge survey, the satisfaction scale of 
internal and external clients, the satisfaction scale of patients, 
the checklist to evaluate a safety management infrastructure 
at a sponsor center, and the checklist to evaluate a safety 
management infrastructure at the investigational sites), are 
shown in  Supplementary file 1, Section 4. 
The cutoffs determined the reach of their range limit for each 
category of evaluation. In all the cases, the subtraction of the 
limit value (N) minus the average value of the item (AR) is 
less than the value of the respective cutoff. 
Finally, after the analyses of this round, the items and 
questions fall into the category of “very adequate,” with a high 
degree of relevance since there were no negative votes. 
Anyway, clarification in respect to items that are adequate 
response options, but which require some drafting 
modification, were considered. The instruments were resent 
to the experts for a second round and all of them maintained 
stability in their answers. 
After the second round, 100% of the consulted experts 
maintained stability of their approaches valuing the questions 
of the questionnaire like very adequate. They considered 
that the structure of questions or items that compose all the 
questionnaires is enough for the investigation. Then, it was 
not necessary to carry out a new round.
For the other three instruments (checklists that evaluate 
adherence to regulatory requirements of essential documents), 
all the items were qualified as very adequate. That is why it 
was not necessary to represent the application of the Delphi 
method.
Pre-test
The instruments validated by the panel of experts were 
considered appropriate and comprehensible in pre-test. All 
the responders were agreed with the response options, the 
application easiness and the extent of each instrument. No 
one suggested modifications. 
Evaluation of Reliability
Respect the reliability for the knowledge survey was obtained 
α = .7124, a value of α = .7251 for the satisfaction survey 
of internal and external clients, α = .9336 for the patient 
satisfaction survey, α = .9023 for the infrastructure checklist 
in the sponsoring centre and .8493 for the infrastructure 
checklist in the sites. For checklists that assess adherence 
of investigator brochure, protocols and informed consent 
documents to the regulatory requirements, were obtained α 
values of .6632, .7060, and .7025 respectively. 
Discussion 
This study ensures the validity and reliability of eight 
instruments that will be the base of indicators for the 
systematic evaluation of the drug safety management at the 
Molecular Immunology Center. It is a part of a strategy for 
strengthening and complementing the global management of 
clinical trials. 
Several authors agree with the need to design and validate new 
measuring instruments when there is no other one capable 
to measure what is needed.30,34 The framework of structure, 
process, and outcome for the organization of quality metrics 
was useful in defining drug safety management during clinical 
trials so that it can be measured and evaluated according to 
GCP requirements.
In a case study12 conducted by Pfizer and Avoca groups with 
the goal of implementing a framework for the oversight and 
analysis of Pfizer’s overall clinical trial quality, they defined 
outcome, predictor and contributor metrics. Although they 
established seven major categories for the quality outcomes 
and for all of them defined their outcome components. The 
results of the implementation of this approach did not take 
part of this manuscript. The majority of the aspects considered 
in the study mentioned in respect to the clinical trial safety 
management were taken into account in our study.
The designed knowledge survey will contribute to assessing 
systematically the level of training required by clinical trial 
participants for the proper identification and management of 
adverse events at the research site. This will help reduce the 
inconsistencies in adverse event classification and report in 
clinical trials. 
The role of effective training for professional develops and 
obtains adequate knowledge in a highly specialized field 
of clinical research is as imperative as to define the various 
levels of training required for these professionals.35 To assure 
the investigator’s sensitivity to this point is one of the key 
responsibilities of the sponsor, which includes proper training 
of the investigative site personnel regarding the use of the 
relevant diagnostic terms for consistent data collection and 
reporting.28
All the checklists designed will help to control the management 
of the process in a systematic way, both in the context of the 
sponsor and in the research sites. 
The use of GCP compliance checklists also supports to 
put plans into action to prevent future noncompliance in 
identified areas. Checklist results often suggest the potential 
root cause of noncompliance. Once the root cause is identified, 
Table. Results of the Self-assessment Survey for Determining the Performance Coefficient of Experts
E1 E2 E3 E4 E5 E6 E7 E8 E9 E10 E11 E12 E13  E14 E15 E16 E17
K 0.85 0.80 0.45 0.95 0.60 0.95 0.70 0.70 0.55 0.80 0.65 0.95 0.55 0.55 0.90 0.65 0.80
H x x x x x x x x
M x x x x x x x x
L x
Abbreviations: En, expert; K, competence coefficient; H, high level of competence; M, medium; L, low level of competence.
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clinical operations can develop corrective actions to remedy 
immediate issues, and design preventative actions to avoid 
future noncompliance in the identified area.36,37 
The designed satisfaction surveys will contribute to the 
systematic evaluation of the perception of those involved in 
the process. We introduce the satisfaction of the different 
stakeholders with the process as a very important outcome 
because the systematic perception of each implicated can help 
to estimate the performance in several manners, facilitating to 
reach a proactive risk and safety management.17 The manner 
in which safety experiences are currently elicited during 
discussions with patients by the investigator and his/her staff 
during visits or at other times is one of the most important 
issues that is rarely addressed.28 On the other hand, the 
communication between the pharmaceutical industry and 
regulator on potential safety concerns must be frequent and 
systematic.14,16 Nelson mentioned the patient satisfaction as a 
quality metric for a clinical trial performance improvement 
since a holistic perspective.37 
There are different criteria regarding the definition of the 
number of experts needed for the panel, but the majority 
recommends that the number of experts should range from 5 
to 15 members, that should possess experience in the treated 
topic and independence in the evaluation approaches.30,33,38 
In respect to the approaches of quantitative analysis of expert 
answers, besides completing the punctuations proposed 
for the estimate of the items, the qualitative contributions 
improved the validation process. This result is common when 
the Delphi method is applied.30,38,39 
The qualification of very adequate was expected for the items 
of the three checklists that evaluate adherence to regulatory 
requirements of essential documents since these items were 
elaborated taken into account the recommendations of the 
international current regulations. The fact that, after the 
second round, all the items or questions of each instrument 
were qualified as VA, QA or adequate, suggests a high 
percentage of agreement among the evaluators. 
Cronbach Alpha test is the most widely used method for 
the analysis of reliability when expressing to what extent the 
answers are related to each other, or measuring the same things 
it can also be added to a unique total punctuation.30,32 
The internal consistency was good for the satisfaction 
survey of patients, internal and external clients, as well as the 
checklist for infrastructure in the research center and at the 
investigational sites. The knowledge survey was acceptable, 
just like the checklists that assess adherence to protocols and 
informed consent documents to regulatory requirements. 
While the checklist that assesses adherence of investigator 
brochure to regulatory requirements reached a value discreetly 
below the acceptable limit of reliability.
These instruments were validated in real trials. From each one, 
we are designing indicators and standards that will provide a 
performance measure of the drug safety management. We are 
working on the implementation of a continuous improvement 
strategy related to that, but the results are not discussed here. 
The instruments could be used as part of any drug safety 
management system, despite the application of technological 
supports, the company size, and geography. We suggest their 
application for the diagnosis of the state of the system the 
first time. Then, the instruments related to the structure of 
the process must be applied at least once a year, and every 
three months those instruments for the process and outcome 
features. 
Another aspect of the drug safety management process such 
as the time to send the expedited report from the site to 
the sponsor and from this to the regulatory agency and the 
adequate description and completeness of the document, 
need to be measured. That is the limitation of the study, 
and the fact that another validation as intra or interobserver 
reproducibility was not addressed. 
Conclusion 
The structure, process and outcome framework allowed the 
characterization of drug safety management during clinical 
trials, providing a useful approach for the promoter to 
systematically measure and evaluate the process. The eight 
instruments proposed in this study are reliable, feasible and 
easy to use for examining drug safety management during the 
clinical trials conduct.
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